Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.
|Number of pages||1|
|Journal||Journal of Biotechnology|
|Early online date||16 Aug 2017|
|Publication status||Published - 30 Aug 2017|
|Event||European biotechnology Congress 2017 - Rixos Libertas, Dubrovnik, Croatia|
Duration: 25 May 2017 → 27 May 2017